Investigational drug · Phase 2
DM-101PX
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Birch Pollen Allergy.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 31, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
3
Any phase or sponsor naming "DM-101PX"
First trial start
2025
Sep 26, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "DM-101PX", any sponsor or status.
Conditions studied
As listed on its trial records.
- Birch Pollen Allergy
Largest trials
Live from ClinicalTrials.gov: studies naming "DM-101PX" as an intervention, largest first.
Desentum OyIndustry
NCT07254871 · 97 participants · Start Sep 26, 2025 · Primary completion Apr 15, 2026
Drug: DM-101PX; Placebo · For: Birch Pollen Allergy
Sites: Mississauga, Canada
Desentum OyIndustry
NCT07898800 · 40 participants (planned) · Start Oct 29, 2026 · Primary completion Mar 2027
Drug: DM-101PX; Placebo · For: Birch Pollen Allergy
Sites: Hanover, Germany
Desentum OyIndustry
NCT06037148 · 30 participants · Start Sep 7, 2023 · Primary completion Mar 6, 2024
Drug: DM-101PX; Placebo to Match DM-101PX · For: Birch Pollen Allergy
Sites: Mississauga, Canada
Newest research
PubMed records naming it or its code names, newest first.
- Subcutaneous Allergen Immunotherapy With Thermosensitive Hydrogel and Recombinant Birch Pollen Allergen Variant, a Randomised Controlled Trial.
Nilson A, Couroux P, Haka J, et al. · Clin Exp Allergy 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.